Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Go back to Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 43.96 +1.15 (2.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.81 | 52 Week High | $59.00 | |||
| Open | $42.97 | 52 Week Low | $32.80 | |||
| Day High | $44.11 | P/E | N/A | |||
| Day Low | $42.94 | EPS | $0.00 | |||
| Volume | 12,717,166 | |||||
